Reuters logo
2 个月前
BRIEF-Astellas, Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide
2017年6月9日 / 中午12点20分 / 2 个月前

BRIEF-Astellas, Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide

June 9 (Reuters) - Pfizer Inc

* Astellas and Pfizer announce amendment to clinical research protocol for phase 3 prosper trial of enzalutamide in patients with non-metastatic castration-resistant prostate cancer

* Pfizer Inc- Companies now anticipate prosper top-line results will be disclosed later this year

* Pfizer Inc- previously expected primary completion date for prosper was June 2019

* Says amendment accelerates anticipated prosper top-line results by two years

* Says target sample size reduced to approximately 1,440 patients and estimated primary completion date is June 2017

* Says primary endpoint remains same: metastasis-free survival

* Says main purpose of amendment is to revise plan for analyses of primary and several secondary endpoints Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below